Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.
Identifieur interne : 003358 ( PubMed/Corpus ); précédent : 003357; suivant : 003359Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.
Auteurs : Frédéric Amant ; Anne Floquet ; Michael Friedlander ; Gunnar Kristensen ; Sven Mahner ; Eun Ji Nam ; Matthew A. Powell ; Isabelle Ray-Coquard ; Nadeem Siddiqui ; Peter Sykes ; Anneke M. Westermann ; Beatrice SeddonSource :
- International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [ 1525-1438 ] ; 2014.
English descriptors
- KwdEn :
- MESH :
Abstract
Endometrial stromal sarcoma (ESS) accounts for approximately 20% of all uterine sarcomas and presents, at a mean age, around 50 years of age. Half of the patients are premenopausal. ESS often manifests as an endometrial polyp and 60% of cases present with FIGO stage I disease. The natural history is one of slow growing indolent disease. Typical microscopic findings include a uniform population of endometrial stromal-type cells invading the myometrium and myometrial vessels. Imaging studies cannot reliably diagnose ESS preoperatively, so surgical resection for a presumed fibroid is a common scenario. Hysterectomy is the cornerstone of treatment for localized ESS, but morcellation should be avoided. Systematic lymphadenectomy in ESS does not improve the outcome. Leaving the ovaries in situ does not worsen survival and this is of importance especially for young women. The data support the current practice to administer adjuvant hormonal treatment, although several questions remain, such as optimal doses, regimens (progestins or aromatase inhibitors) and duration of therapy. Repeat surgery for recurrent disease that is indolent and hormone sensitive appears to be an acceptable approach. Systemic treatment for recurrent disease is mainly hormonal.
DOI: 10.1097/IGC.0000000000000205
PubMed: 25033257
Links to Exploration step
pubmed:25033257Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.</title><author><name sortKey="Amant, Frederic" sort="Amant, Frederic" uniqKey="Amant F" first="Frédéric" last="Amant">Frédéric Amant</name><affiliation><nlm:affiliation>*EORTC, Department of Oncology, KU Leuven and Department of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium; †GINECO, Department of Medical Oncology, Institut Bergonié, Bordeaux, France; ‡ANZGOG, Department of Clinical Oncology, Prince of Wales Hospital, Randwick, Australia; §NSGO, Department for Gynecologic Oncology and Institute for Medical Informatics, Oslo University Hospital, Oslo, Norway; ∥AGO, Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ¶KGOG, Women's Cancer Clinic, Division of Gynecologic Oncology, Institute of Women's Life Medical Science, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, South Korea; #GOG, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, United States of America, **GINECO, Centre Léon Bérard, Lyon, France; ††SGCTG, Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, United Kingdom; ‡‡ANZGOG, Department of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand; §§DGOG, Department of Medical Oncology, Academic Medical Center, Amsterdam, the Netherlands; and ∥∥MRCP, FRCR, Department of Oncology, University College Hospital London, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Floquet, Anne" sort="Floquet, Anne" uniqKey="Floquet A" first="Anne" last="Floquet">Anne Floquet</name></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name></author><author><name sortKey="Kristensen, Gunnar" sort="Kristensen, Gunnar" uniqKey="Kristensen G" first="Gunnar" last="Kristensen">Gunnar Kristensen</name></author><author><name sortKey="Mahner, Sven" sort="Mahner, Sven" uniqKey="Mahner S" first="Sven" last="Mahner">Sven Mahner</name></author><author><name sortKey="Nam, Eun Ji" sort="Nam, Eun Ji" uniqKey="Nam E" first="Eun Ji" last="Nam">Eun Ji Nam</name></author><author><name sortKey="Powell, Matthew A" sort="Powell, Matthew A" uniqKey="Powell M" first="Matthew A" last="Powell">Matthew A. Powell</name></author><author><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name></author><author><name sortKey="Siddiqui, Nadeem" sort="Siddiqui, Nadeem" uniqKey="Siddiqui N" first="Nadeem" last="Siddiqui">Nadeem Siddiqui</name></author><author><name sortKey="Sykes, Peter" sort="Sykes, Peter" uniqKey="Sykes P" first="Peter" last="Sykes">Peter Sykes</name></author><author><name sortKey="Westermann, Anneke M" sort="Westermann, Anneke M" uniqKey="Westermann A" first="Anneke M" last="Westermann">Anneke M. Westermann</name></author><author><name sortKey="Seddon, Beatrice" sort="Seddon, Beatrice" uniqKey="Seddon B" first="Beatrice" last="Seddon">Beatrice Seddon</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:25033257</idno><idno type="pmid">25033257</idno><idno type="doi">10.1097/IGC.0000000000000205</idno><idno type="wicri:Area/PubMed/Corpus">003358</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003358</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.</title><author><name sortKey="Amant, Frederic" sort="Amant, Frederic" uniqKey="Amant F" first="Frédéric" last="Amant">Frédéric Amant</name><affiliation><nlm:affiliation>*EORTC, Department of Oncology, KU Leuven and Department of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium; †GINECO, Department of Medical Oncology, Institut Bergonié, Bordeaux, France; ‡ANZGOG, Department of Clinical Oncology, Prince of Wales Hospital, Randwick, Australia; §NSGO, Department for Gynecologic Oncology and Institute for Medical Informatics, Oslo University Hospital, Oslo, Norway; ∥AGO, Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ¶KGOG, Women's Cancer Clinic, Division of Gynecologic Oncology, Institute of Women's Life Medical Science, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, South Korea; #GOG, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, United States of America, **GINECO, Centre Léon Bérard, Lyon, France; ††SGCTG, Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, United Kingdom; ‡‡ANZGOG, Department of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand; §§DGOG, Department of Medical Oncology, Academic Medical Center, Amsterdam, the Netherlands; and ∥∥MRCP, FRCR, Department of Oncology, University College Hospital London, London, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Floquet, Anne" sort="Floquet, Anne" uniqKey="Floquet A" first="Anne" last="Floquet">Anne Floquet</name></author><author><name sortKey="Friedlander, Michael" sort="Friedlander, Michael" uniqKey="Friedlander M" first="Michael" last="Friedlander">Michael Friedlander</name></author><author><name sortKey="Kristensen, Gunnar" sort="Kristensen, Gunnar" uniqKey="Kristensen G" first="Gunnar" last="Kristensen">Gunnar Kristensen</name></author><author><name sortKey="Mahner, Sven" sort="Mahner, Sven" uniqKey="Mahner S" first="Sven" last="Mahner">Sven Mahner</name></author><author><name sortKey="Nam, Eun Ji" sort="Nam, Eun Ji" uniqKey="Nam E" first="Eun Ji" last="Nam">Eun Ji Nam</name></author><author><name sortKey="Powell, Matthew A" sort="Powell, Matthew A" uniqKey="Powell M" first="Matthew A" last="Powell">Matthew A. Powell</name></author><author><name sortKey="Ray Coquard, Isabelle" sort="Ray Coquard, Isabelle" uniqKey="Ray Coquard I" first="Isabelle" last="Ray-Coquard">Isabelle Ray-Coquard</name></author><author><name sortKey="Siddiqui, Nadeem" sort="Siddiqui, Nadeem" uniqKey="Siddiqui N" first="Nadeem" last="Siddiqui">Nadeem Siddiqui</name></author><author><name sortKey="Sykes, Peter" sort="Sykes, Peter" uniqKey="Sykes P" first="Peter" last="Sykes">Peter Sykes</name></author><author><name sortKey="Westermann, Anneke M" sort="Westermann, Anneke M" uniqKey="Westermann A" first="Anneke M" last="Westermann">Anneke M. Westermann</name></author><author><name sortKey="Seddon, Beatrice" sort="Seddon, Beatrice" uniqKey="Seddon B" first="Beatrice" last="Seddon">Beatrice Seddon</name></author></analytic><series><title level="j">International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</title><idno type="eISSN">1525-1438</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Combined Modality Therapy</term><term>Consensus</term><term>Endometrial Neoplasms (pathology)</term><term>Endometrial Neoplasms (therapy)</term><term>Female</term><term>Humans</term><term>Medical Oncology</term><term>Practice Guidelines as Topic</term><term>Sarcoma, Endometrial Stromal (pathology)</term><term>Sarcoma, Endometrial Stromal (therapy)</term><term>Societies, Medical</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Endometrial Neoplasms</term><term>Sarcoma, Endometrial Stromal</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Endometrial Neoplasms</term><term>Sarcoma, Endometrial Stromal</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Combined Modality Therapy</term><term>Consensus</term><term>Female</term><term>Humans</term><term>Medical Oncology</term><term>Practice Guidelines as Topic</term><term>Societies, Medical</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Endometrial stromal sarcoma (ESS) accounts for approximately 20% of all uterine sarcomas and presents, at a mean age, around 50 years of age. Half of the patients are premenopausal. ESS often manifests as an endometrial polyp and 60% of cases present with FIGO stage I disease. The natural history is one of slow growing indolent disease. Typical microscopic findings include a uniform population of endometrial stromal-type cells invading the myometrium and myometrial vessels. Imaging studies cannot reliably diagnose ESS preoperatively, so surgical resection for a presumed fibroid is a common scenario. Hysterectomy is the cornerstone of treatment for localized ESS, but morcellation should be avoided. Systematic lymphadenectomy in ESS does not improve the outcome. Leaving the ovaries in situ does not worsen survival and this is of importance especially for young women. The data support the current practice to administer adjuvant hormonal treatment, although several questions remain, such as optimal doses, regimens (progestins or aromatase inhibitors) and duration of therapy. Repeat surgery for recurrent disease that is indolent and hormone sensitive appears to be an acceptable approach. Systemic treatment for recurrent disease is mainly hormonal.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25033257</PMID><DateCreated><Year>2014</Year><Month>10</Month><Day>28</Day></DateCreated><DateCompleted><Year>2015</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2014</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1525-1438</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>9 Suppl 3</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</Title><ISOAbbreviation>Int. J. Gynecol. Cancer</ISOAbbreviation></Journal><ArticleTitle>Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.</ArticleTitle><Pagination><MedlinePgn>S67-72</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/IGC.0000000000000205</ELocationID><Abstract><AbstractText>Endometrial stromal sarcoma (ESS) accounts for approximately 20% of all uterine sarcomas and presents, at a mean age, around 50 years of age. Half of the patients are premenopausal. ESS often manifests as an endometrial polyp and 60% of cases present with FIGO stage I disease. The natural history is one of slow growing indolent disease. Typical microscopic findings include a uniform population of endometrial stromal-type cells invading the myometrium and myometrial vessels. Imaging studies cannot reliably diagnose ESS preoperatively, so surgical resection for a presumed fibroid is a common scenario. Hysterectomy is the cornerstone of treatment for localized ESS, but morcellation should be avoided. Systematic lymphadenectomy in ESS does not improve the outcome. Leaving the ovaries in situ does not worsen survival and this is of importance especially for young women. The data support the current practice to administer adjuvant hormonal treatment, although several questions remain, such as optimal doses, regimens (progestins or aromatase inhibitors) and duration of therapy. Repeat surgery for recurrent disease that is indolent and hormone sensitive appears to be an acceptable approach. Systemic treatment for recurrent disease is mainly hormonal.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Amant</LastName><ForeName>Frédéric</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>*EORTC, Department of Oncology, KU Leuven and Department of Gynecologic Oncology, University Hospitals Leuven, Leuven, Belgium; †GINECO, Department of Medical Oncology, Institut Bergonié, Bordeaux, France; ‡ANZGOG, Department of Clinical Oncology, Prince of Wales Hospital, Randwick, Australia; §NSGO, Department for Gynecologic Oncology and Institute for Medical Informatics, Oslo University Hospital, Oslo, Norway; ∥AGO, Department of Gynecology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; ¶KGOG, Women's Cancer Clinic, Division of Gynecologic Oncology, Institute of Women's Life Medical Science, Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul, South Korea; #GOG, Department of Obstetrics and Gynecology, Washington University School of Medicine, St. Louis, MO, United States of America, **GINECO, Centre Léon Bérard, Lyon, France; ††SGCTG, Department of Gynaecological Oncology, Glasgow Royal Infirmary, Glasgow, United Kingdom; ‡‡ANZGOG, Department of Obstetrics and Gynaecology, University of Otago, Christchurch, New Zealand; §§DGOG, Department of Medical Oncology, Academic Medical Center, Amsterdam, the Netherlands; and ∥∥MRCP, FRCR, Department of Oncology, University College Hospital London, London, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Floquet</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Friedlander</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Kristensen</LastName><ForeName>Gunnar</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Mahner</LastName><ForeName>Sven</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Nam</LastName><ForeName>Eun Ji</ForeName><Initials>EJ</Initials></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Matthew A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Ray-Coquard</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Siddiqui</LastName><ForeName>Nadeem</ForeName><Initials>N</Initials></Author><Author ValidYN="Y"><LastName>Sykes</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Westermann</LastName><ForeName>Anneke M</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Seddon</LastName><ForeName>Beatrice</ForeName><Initials>B</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Int J Gynecol Cancer</MedlineTA><NlmUniqueID>9111626</NlmUniqueID><ISSNLinking>1048-891X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="N">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016889" MajorTopicYN="N">Endometrial Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008495" MajorTopicYN="Y">Medical Oncology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017410" MajorTopicYN="Y">Practice Guidelines as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018203" MajorTopicYN="N">Sarcoma, Endometrial Stromal</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012955" MajorTopicYN="N">Societies, Medical</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>7</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25033257</ArticleId><ArticleId IdType="doi">10.1097/IGC.0000000000000205</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003358 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003358 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25033257
|texte= Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25033257" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |